Company news
Chosa Oncology AB news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Chosa Oncology announces the result of exercise of warrants TO2
July 15, 2026
CHOSA: Chosa Oncology announces the result of exercise of warrants TO2
July 15, 2026
Members of executive management participate in the ongoing warrant - exercise ending tomorrow
July 13, 2026
CHOSA: Members of executive management participate in the ongoing warrant - exercise ending tomorrow
July 13, 2026
CHOSA: CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP
July 10, 2026
CHOSA Oncology in connection with the TO2 warrant exercise
July 1, 2026
CHOSA: CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP
June 23, 2026
CHOSA: Strategic progress and positive clinical data drive momentum, supported by strengthened finances
May 27, 2026
Årsredovisning 2025 (in English - unofficial translation) (CHOSA Oncology AR 2025 UK Version)
May 9, 2026
Annual report 2025 (in English - unofficial translation) (CHOSA Oncology AR 2025 UK Version)
May 9, 2026
Chosa Oncology: Proposal for resolution on authorization regarding issues (Proposal for resolution on authorization regarding issues 2026 4gdr)
April 24, 2026
Power of Attorney (Power of Attorney 2026 m52n)
April 24, 2026
Notice of annual general meeting (Notice of annual general meeting 2026 reem)
April 24, 2026
Chosa Oncology: Proposal for resolution on authorization regarding issues (Proposal for resolution on authorization regarding issues 2026)
April 24, 2026
Notice of annual general meeting (Notice of annual general meeting 2026)
April 24, 2026
Power of Attorney (Power of Attorney 2026)
April 24, 2026
Chosa Oncology to present new Platin-DRP® data at ASCO 2026
April 24, 2026
CHOSA: CHOSA to present new Platin-DRP® data at ASCO 2026
April 24, 2026
CHOSA: High Platin-DRP® scores predict significantly longer survival in advanced NSCLC
March 26, 2026
Årsredovisning 2025 (in English) (CHOSA Oncology 2025 Year End Report UK 899x)
March 23, 2026
Annual report 2025 (CHOSA Oncology 2025 Year End Report UK)
March 23, 2026
Chosa Oncology to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress
March 19, 2026
CHOSA: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress
March 19, 2026
CHOSA: Platin-DRP® showed strong clinical progress in 2025, with funding secured into 2027
February 26, 2026
Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy
January 23, 2026
CHOSA: Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy
January 23, 2026
CHOSA: Significant clinical progress and strengthened financial position with new capital raised in Q3 2025
November 13, 2025
CHOSA: Strong Q2 results, clinical progress, and capital raises position for key data in Q3 2025
August 28, 2025
CHOSA: Proprietary technology doubles chemo efficacy, with key clinical and partnership milestones ahead
June 17, 2025
CHOSA: DRP® platform expansion and clinical progress drive CHOSA Oncology's Q1 2025 focus
May 30, 2025
CHOSA: Net loss narrows as CHOSA Oncology advances clinical validation but faces funding risks
February 28, 2025
CHOSA: Q3 net loss narrowed, financials strengthened, and board expertise expanded with Prof. Hirsch
November 11, 2024
CHOSA: Q2 loss narrowed and cash reserves grew as CHOSA advanced oncology partnerships and technology
August 30, 2024